Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Open Access
- 6 October 1994
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 331 (14) , 896-903
- https://doi.org/10.1056/nejm199410063311402
Abstract
About 65 percent of previously untreated adults with primary acute myeloid leukemia (AML) enter complete remission when treated with cytarabine and an anthracycline. However, such responses are rarely durable when conventional postremission therapy is administered. Uncontrolled trials have suggested that intensive postremission therapy may prolong these complete remissions.Keywords
This publication has 44 references indexed in Scilit:
- A successful system of scientific data audits for clinical trials. A report from the Cancer and Leukemia Group BPublished by American Medical Association (AMA) ,1993
- Short‐term remission induction and consolidation therapy for adult acute myelogenous leukemiaHematological Oncology, 1991
- CHEMOTHERAPY VERSUS TRANSPLANTATION IN ACUTE LEUKAEMIABritish Journal of Haematology, 1989
- The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemiaBritish Journal of Haematology, 1987
- PRINCIPAL RESULTS OF THE MEDICAL RESEARCH COUNCIL'S 8th ACUTE MYELOID LEUKAEMIA TRIALThe Lancet, 1986
- In adult acute nonlymphoblastic leukaemia extended maintenance chemotherapy has no benefitAmerican Journal of Hematology, 1984
- ACUTE MYELOID LEUKAEMIA: IS ‘CONSOLIDATION’THERAPY NECESSARY?British Journal of Haematology, 1984
- Distribution of 250 Cases of Acute Myeloid Leukaemia (AML) according to the FAB Classification and Response to TherapyBritish Journal of Haematology, 1981
- Failure of remission induction in acute myelocytic leukemiaMedical and Pediatric Oncology, 1978
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958